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Abstract
Despite advanced immunosuppression, redundancy in the molecular diversity of acute rejection (AR) often results in
incomplete resolution of the injury response. We present a bioinformatics based approach for identification of these
redundant molecular pathways in AR and a drug repositioning approach to suppress these using FDA approved drugs
currently available for non-transplant indications. Two independent microarray data-sets from human renal allograft
biopsies (n = 101) from patients on majorly Th1/IFN-y immune response targeted immunosuppression, with and without AR,
were profiled. Using gene-set analysis across 3305 biological pathways, significant enrichment was found for the IL17
pathway in AR in both data-sets. Recent evidence suggests IL17 pathway as an important escape mechanism when Th1/IFN-
y mediated responses are suppressed. As current immunosuppressions do not specifically target the IL17 axis, 7200
molecular compounds were interrogated for FDA approved drugs with specific inhibition of this axis. A combined IL17/IFN-y
suppressive role was predicted for the antilipidemic drug Fenofibrate. To assess the immunregulatory action of Fenofibrate,
we conducted in-vitro treatment of anti-CD3/CD28 stimulated human peripheral blood cells (PBMC), and, as predicted,
Fenofibrate reduced IL17 and IFN-c gene expression in stimulated PMBC. In-vivo Fenofibrate treatment of an experimental
rodent model of cardiac AR reduced infiltration of total leukocytes, reduced expression of IL17/IFN-y and their pathway
related genes in allografts and recipients’ spleens, and extended graft survival by 21 days (p,0.007). In conclusion, this
study provides important proof of concept that meta-analyses of genomic data and drug databases can provide new
insights into the redundancy of the rejection response and presents an economic methodology to reposition FDA approved
drugs in organ transplantation.
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Introduction
There is an unmet clinical need for novel immunmodulatory
drugs in transplantation, as redundant alloimmune mechanisms,
not adequately targeted by current immunosuppressive drugs,
require additional modulation to mitigate the development of graft
injury, chronic allograft damage and premature graft loss. Better
understanding of some of these redundant immune responses may
allow for the identification of novel drug targets and drugs for
improved post-transplant patient care.
We hypothesized, that the application of a bioinformatics based
genomic drug target discovery that uses publicly available
functional data in conjunction with the concept of repositioning
already FDA approved drugs, represents a promising approach for
transplantation medicine which has a finite market size, to identify
novel treatment options. This approach has been previously
successfully applied by us in inflammatory bowel disease [1], and is
now focused on human renal acute allograft rejection (AR).
Initial discovery of escape mechanisms in transplant rejection
was done by whole genome microarray analyses of renal
transplant recipient biopsies with AR. Analyses focused on bio-
databases of functional gene-sets and pathways and discovered
biologically relevant transcriptional changes in kidney allograft
AR. We identified the Interleukin- (IL) 17 pathway as a pivotal
redundant pathway in transplant rejection under the umbrella of
Calcineurin inhibitor based immunosuppression (Tacrolimus,
Cyclosporine). Recent evidence has hypothesized IL17 as a poten-
tial escape mechanism in AR if IFN-y mediated/Th1 responses
are suppressed as is with Calcineurin inhibitors [2].
IL17 acts as pro-inflammatory cytokine promoting neutrophil
and monocyte recruitment to sites of inflammation usually under
the influence of IL-1b, IL-6, and tumor necrosis factor (TNF), and
interferon (IFN)-c [3]. Transcription and production of IL17
during AR occurs in multiple cell-types and is not limited to the
Th-subpopulation: IL17 can be expressed by innate and adaptive
immune cells, particularly by neutrophils, macrophages, dendritic
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cells, CD4+ and CD8+ T-cells, in addition to endothelial and
epithelial cells [4–7]. IL17+ cells in biopsies from kidney transplant
recipients correlated with the degree of inflammation during AR
and independently predicted graft dysfunction at the last follow up
[6]. Our results together with other previously published data
suggested that IL17 could be an attractive drug target for
transplant medicine [8,9]. Currently, there is no FDA approved
small molecule drug to regulate IL17 responses and antagonizing
IL17 in transplantation is not an approved indication.
Bioinformatic analyses of the genomic and drug databases
identified Fenofibrate as a drug with established human safety that
regulates IL17 and IFN-y responses and thus could be repositioned
for treatment of the IL17 mediated axis of allograft AR.
Fenofibrate previously attenuated IFN-c and IL17 mediated
experimental colitis [10] and has also reduced systemic in-
flammatory effects in patients with metabolic syndrome [11]
within clinical studies. In addition, we selected Fenofibrate for our
drug repositioning studies as it is a small molecule drug for oral
application, with proven administration, distribution, metabolism
and excretion (ADME) profile, and has extensive human safety
data with tolerable side effects.
Study Design
The study was based on human tissue-specific acute rejection
(AR) injury pathway discovery, their application towards inferred
drug targets, and the validation of selected drugs for abrogation of
experimental graft rejection by in vitro and in vivo methods
(Figure 1). The first phase of this study consisted of a whole
genome microarray discovery phase in humans for rejection
specific transcriptional analyses of implantation (33 D0) and their
paired post-transplant rejecting (17 AR) and non-rejecting (16
STA) biopsies. All 66 biopsies were blindly scored by the same
pathologist (Neeraja Kambham, Stanford University, CA) and
rejection was graded by the Banff criteria [12]. Three computa-
tional databases (MSigDb=molecular Signatures database;
SMD=Stanford Microarray database; AcIc = activated immune
cells) were analyzed for significant enrichment of pathways and
networks (GSA=Gene set analysis) that were redundant in AR.
For validation, an additional microarray data-set from 35 renal
allograft biopsies (21 STA, 14 AR) from adult recipients post
transplantation was interrogated which was downloaded from
Gene Expression Omnibus (GEO, GSE9493). The IL17 rejection-
specific pathway, chosen as one of the most significant pathway in
AR in both data-sets was aligned to a drug database with PubMed
proven interactions to the input target genes, resulting in the
selection of an FDA approved small molecule drug, Fenofibrate,
for possible drug repositioning. Fenofibrate was identified to
additionally target the IFN-c pathway. Initial validation of the
effect of Fenofibrate was done to examine its regulation of IL17
and IFN-c in vitro in human peripheral blood mononuclear cells
(PBMC) stimulated with anti CD3/anti CD28. Next, Fenofibrate
was tested for its efficacy to improve acute tissue rejection and
prolong allograft survival in vivo in an experimental model of
heterotopic cardiac AR. End-points examined were reduction of
inflammation in the graft, and extension of graft survival
compared to non-treatment (NT) and standard immunosuppres-
Figure 1. Study Design. Whole genome microarrays from 66 pre- and post-transplant kidney graft biopsies and from 35 post-transplant kidney
graft biopsies were analyzed for rejection specific injury pathways using 3 computational databases comprising 3305 independent gene-sets. AR
specific IL17 pathway (FDR=0.3, p = 0.011) and activated IL17+ T-helper cells cell (FDR= 0.5; p = 0.008) gene-sets were aligned to a database of 7200
compounds with proven interactions with the input genes (MetaCoreTM, GeneGo, Thomson Reuters) resulting in the identification of Fenofibrate for
drug repositioning in AR. Efficacy of Fenofibrate was tested in vitro using human PBMC and in vivo in mouse total allo-mismatch cardiac rejection for
anti-inflammatory and for its potency to prolong graft survival.
doi:10.1371/journal.pone.0056657.g001
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sion (Cyclosporine, Cys) applying Flow cytometry (FACS),
histology and assessment of graft function by palpation. Local
and systemic efficacy of Fenofibrate to regulate IL17 pathway and
IFN-y pathway response genes was characterized by quantitative
PCR (QPCR) in mice grafts and spleens at post-operative day
(POD) 7 and compared to NT and Cys (Figure 1).
Materials
Patients and Transplant Biopsies
In our data-set of 66 renal transplant biopsies from 33 unique
pediatric and young adult patients (age range 4–22) were
examined. To minimize baseline confounders inclusion criteria
were young donor age (7–30 years), no delayed graft function,
unsensitized recipients (peak panel reactive antibody ,20%), and
similar immunosuppression (Daclizumab induction, mycopheno-
late mofetil (MMF), tacrolimus (Tac)) (Table 1). Excluded were
expanded criteria donor kidneys, as they are not used for pediatric
and adolescent recipients. Each patient had a biopsy profiled at
time of engraftment (D0) prior to reperfusion of the donor kidney,
and within the first year post-transplantation, either for cause or as
part of protocol surveillance. Biopsies were blindly read for
histological evaluation by a single pathologist resulting in 17
patients with Banff graded [12] acute rejection (AR), and 16
patients with essentially normal biopsy reads (no substantive
pathology, negative C4d, CD20 staining) (STA). In the rejection
cohort, 4 biopsies showed relevant cellular infiltrates that were
suspicious for but did not reach the threshold for diagnosis of acute
T-cell mediated rejection and were thus diagnosed as borderline
rejection (BL), 7 biopsies were graded as ARIA and 6 biopsies as
ARIB. All patients gave written informed consent, and the study
was approved by the institutional review board of Stanford
University and adhered to the Declarations of Istanbul and
Helsinki. Written informed consent was obtained and documented
on the consent form from the next of kin, caretakers, or guardians
on the behalf of the minors/children participants involved in the
study and was approved by the ethics committee [13,14].
Demographics and clinical information are summarized in
Table 1. The publicly available data-set (GSE9493) downloaded
from Gene Expression Omnibus (GEO) included data from 35
renal allograft biopsies from adult recipients post transplantation.
This data-set included 21 STA, and 14 rejection cases. Within the
rejection group, 4 cases showed abnormalities which were graded
as BL rejection according to Banff [15]. Demographics of these
patients can be found here [16].
Mice for Experimental Transplant Rejection
For in vivo experimental heart transplantation, recipient
C57BL/6J (H2b) and donor FVB (H2q) mice were used (SM
and [8]). All animal experiments were approved by Stanford
University Institutional Animal Care and performed in accor-
dance with the Guide for the Care and Use of Laboratory Animals
(Ref; National Research Council 1996; Guide for the Care and
Use of Laboratory Animals, Washington D.C., National Academy
Press). All surgery was performed under sodium pentobarbital
anesthesia, and all efforts were made to minimize suffering. In
brief, FVB donor hearts were implanted into the abdomen of
C57BL/6 WT mice representing a complete MHC-class 1 and -2
mismatch [17,18]. Animals were divided into treatment (Fenofi-
brate, FF) and no-Treatment (NT) groups, each consisting of 6
animals in the in the 7-day treatment model and consisting of 6
animals in the NT group, 9 animals in the FF group in the 30-day
graft survival study. In the graft survival study, we additionally
added a group of 6 animals that were treated with standard
immunosuppression, Cyclosporine (Cys). Animal activity, body
weight and graft function were assessed daily. The latter was
measured by direct abdominal palpation and expressed as graft
beating score (BS) using the Stanford cardiac surgery laboratory
graft scoring system (0: no contraction; 1: contraction barely
palpable; 2: obvious decrease in contraction strength, but still
contracting in a coordinated manner, rhythm disturbance; 3:
strong, coordinated beat but noticeable decrease in strength or
rate, distention/stiffness; or 4: strong contraction of both
ventricles, regular rate, no enlargement or stiffness).
Concise Methods
Human Tissue Microarray Experiments
Total RNA extraction, quality control, complementary (c)-DNA
amplification and microarray hybridization for human renal
allograft biopsies was essentially performed as published [19]
and described in SM. In brief, total RNA was extracted from
biopsies stored in RNAlater (Ambion, Texas, TX) using TRIzol
Reagent (Invitrogen, Carlsbad, CA). After quality control, RNA
was amplified to cDNA, biotin labeled and hybridized onto
Affymetrix GeneChip Human Genome U133 plus 2.0 Arrays.
Human PBMC Stimulation
Human PBMC for in-vitro drug efficacy assays were isolated
from whole blood of 5 healthy individuals (2 female, 3 males, mean
age 31+/214 years) using Ficoll gradient centrifugation (Ficoll-
PaqueTM PLUS, Amersham Biosciences, Uppsala, Sweden).
Isolated PBMCs were pretreated with 100 mMol Fenofibrate
(Sigma Aldrich, St. Luis, MO) for 2 hours and then stimulated
with anti-human CD3/CD28 antibodies for 65 hours. Thereafter
cells were harvested and snap frozen at 280uC until downstream
analysis of gene expression. In vitro experiments are described in
detail in SM.
Mouse Treatment
Fenofibrate (F6020; Sigma Aldrich, St. Louis, MO) was dosed at
100 mg/kg body weight/day and administered daily either by i.p.
injection in the 7-day inflammatory model, or by oral gavage in
the 30-day graft survival study. Treatment started the day prior to
transplantation and lasted until the day before sacrifice (SM).
Cyclosporine (Cys) was dosed at 20 mg/kg/day and was
administered daily by i.p. injection. The dosage of Cyclosporine
was based on published literature in experimental cardiac allograft
rejection [20], the dosage of Fenofibrate was based on literature of
an experimental mouse model of atherosclerosis that showed
efficacy but no toxicity during the treatment [21]. A 1:1 translation
of either Cyclosporine or of Fenofibrate dosages used to treat
humans were not possible, as the ADME profiles between mice
and humans are not comparable.
Treatment Efficacy Endpoints
Murine cardiac allograft survival. To investigate cardiac
graft survival in transplanted mice, graft beating scores were
determined daily for a maximum of 30 days in Fenofibrate (FF,
n = 9) treated mice, and was compared to non-treated animals
(NT, n= 6), as well as to standard immunosuppression, Cyclo-
sporine (CSA, n= 6) treated animals. Significance between graft
survival between the FF, CSA, and NT groups were assessed by
Wilcoxon log rank test in GraphPad Prism 5.04 (GraphPad
Software Inc., La Jolla, CA). A p-value ,0.05 was considered
significant.
Murine cardiac allograft inflammation. To study anti-
inflammatory effects of Fenofibrate in cardiac AR, animals
Drug Repositioning Fenofibrate for Transplantation
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underwent Fenofibrate treatment for 7 days and the following
assays were performed:
Graft histology at POD7 was evaluated by light microscopy of
hematoxylin and eosin (H&E) stained formalin fixed and paraffin
embedded tissue sections using a Nikon E600 light microscope
(Nikon Instruments Inc., Melville, NY) at 106magnification and
Spot V4.6 imaging software (Spot Imaging, Sterling Heights, MI).
See SM for details.
Fluorescence Activated Cell Sorting (FACS) of graft infiltrating
cells was performed to determine the number of infiltrating cells in
recipient cardiac allografts (CD4+, CD8+, B220+, CD11b+, F4/
80, Gr1.1) at POD7 and has been described by us [8] and can be
found in detail in SM.
Human in vitro and murine in vivo QPCR. For quantifi-
cation of gene expression in in-vitro and in-vivo experiments by
quantitative PCR (QPCR), total RNA from human PBMC was
isolated using the Pico Pure RNA isolation Kit (Arcturus, Life
Technologies, Foster City, CA). Total RNA from mice allograft
and spleen tissues was extracted using TRIzolH Reagent (Invitro-
gen, Life Technologies, Carlsbad, CA) [8]. Each time, 250 ng of
total RNA were reverse transcribed using Superscript II (Invitro-
gen, Life Technologies, Carlsbad, CA). In human PBMC,
expression of 7 genes plus 18S as endogenous control was
analyzed in duplicates by TaqMan QPCR (ABI HT7900 In-
strument, Applied Biosystems, Life Technologies, CA, USA)
according to standard protocols. Data was analyzed using SDS
2.3 software (Applied Biosystems, Life Technologies, Foster City,
CA). Mouse allograft and recipient spleen gene expression was
assessed using the high throughput Fluidigm BioMark instrument
(BioMark; Fluidigm, San Francisco, CA) as described in detail in
SM. In brief, cDNA was amplified for 14 target genes using
Applied Biosystems primers and probes. Preamplified cDNA was
loaded into a Dynamic 96.96 chip (Fluidigm) for a 40 cycle
QPCR. Expression of 18S served as endogenous control, and data
was analyzed in the Biomark RT-PCR analysis software V.2.0.
Assay IDs are listed in SM.
Data Analysis
Microarray data analysis. Affymetrix HG U133 plus2.0
gene chip CEL files from 66 pre-transplant donor samples (D0,
n = 33) and post-transplant Banff graded renal allograft biopsy
samples (STA, n= 16; BL, n= 4; ARIA, n= 7; ARIB, n= 6) were
uploaded into dChip 2006 software [22] for processing and
normalization. Perfect match only for background correction was
performed and arrays were checked for single, array and probe
outliers before quantile normalization and computing of model
based expression values [23]. Only genes with expression values
present on each array were used for analyses. Raw data are stored
in gene expression omnibus (GEO) under GSE34437, sample IDs
used for microarray analyses are listed in Table S1.
To expand the number of patients and to validate the findings
in our data-set an additional microarray data-set (Affymetrix HG
U133 plus2.0) was downloaded from GEO (GSE9493) consisting
of whole genome expression profiles from 21 STA, 4 BL and 10
AR renal allograft biopsies. Data had been preprocessed and
normalized (RMA, Quantile normalization, log2 transformation)
as described [16,24].
Computational analyses of databases for rejection
pathway analysis. Significance analysis of microarrays (SAM,
[25]) for two-class and for quantitative gene-set analysis (GSA)
[26] was performed to detect rejection specific gene-sets in patient
biopsies with AR. Enrichment in AR compared to STA was
identified by two-class GSA. To identify pathways with increasing
enrichment from D0.STA.BL.ARIA.ARIAB quantitative
GSA was applied. GSA uses maxmean statistics and applies
a restandardization of genes and sample permutations to estimate
false discovery rate (FDR) which means that a gene-set must be
unusual both as compared to gene-sets of the same size sampled at
random from the set of genes represented by the gene-set, and as
compared to itself, when the outcome labels are permuted [27,28].
Here, the FDR was calculated in 1000 permutations, and
significance level was set at an FDR of 0.5. Correlation between
gene expression values and phenotype was based on T-test for 2-
class GSA and on regression for quantitative GSA. A total of 3307
Table 1. Patient Demographics.
Score D0 STA BL ARIA ARIB
Number 33 16 4 7 6
Histological diagnosis (Banff) Pre-transplant donor
biopsy
No significant graft
abnormalities
Borderline acute
rejection
Mild-moderate cellular
acute rejection
Severe cellular acute
rejection
% non-protocol / 25% 50% 57% 33.3%
Time post Transplantation
[months]
/ 25.4 (+71/225) 10.2 (+8/25) 12.6 (+19/27) 5.8 (+8/23)
# C4D / 0 0 2 1
# CD20 / 0 0 0 3
Serum Creatinine [mg/mL] / 0.5275 1.075 0.924 0.72
Recipient age 8.3 (+10/26.7) 16.6 (+2/24) 12.3 (+6/24) 11.8 (+6/28) 13.4(+5/210)
Recipient gender [%male] 75% 75% 50% 28.6% 66.7%
Donor age 29.5(+23/215) 31.1 (+16/217) 26.5 (+12/226) 26.7 (+17.3/219) 26.7 (+17/211)
Donor gender [%male] 40.9% 50% 50% 57.1% 83.3%
Immunosuppression / MMF+Tac (9)/Sir (1)/
Aza (1) +/2SB (5)b
MMF+Tac+SB MMF+Tac (4)/Sir
(1)+/2SB (2)
MMF+Tac(2)/Aza
(1)+/2SB (3)
HLA MM a / 1.5 0 0 0
aHLA MM=human leukocyte antigen mismatch;
bSir = Sirolimus; SB = steroid based; Aza =Azathioprine;
doi:10.1371/journal.pone.0056657.t001
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publicly available and manually curated gene-sets, containing
a total of 839,839 genes ( = 20,930 unique genes) were tested.
From the Molecular Signature Database (MSigDb v2.0, Broad
Institute) we downloaded 3272 gene-sets curated using seven
online pathway databases (KEGG; BioCarta, BioScience Corp.,
Reactome, Sigma-Aldrich, Signal transduction knowledge envi-
ronment and signaling gateway), PubMed publications, and
knowledge of domain experts. From the Stanford microarray
database (SMD, http://smd.stanford.edu) 24 gene-sets for cellular
processes were downloaded, and an additional dataset of Activated
Immune Cells (AcicDb) consisting of 9 gene-sets were manually
created by us using publicly available microarray gene expression
data of in-vitro activated T-helper lymphocytes (Th) (Th1, Th2,
IL17+ T-helper cells), antigen presenting cells (dendritic cells (DC),
natural killer (NK) cells) and cells of the innate immune system
(monocytes, neutrophils). Detailed gene-set descriptions are listed
in Table S2.
Multivariate analysis of gene expression for IL17 pathway
and IL17+ T-helper cells genes. To confirm GSA results,
unsupervised Principal Component Analysis (PCA) and hierarchi-
cal clustering were performed for the IL17 pathway and Th17
gene-set genes in AR and STA (Partek Genomics Suite V.6.6,
Partek Inc. USA). In case of multiple array probe-sets for the same
gene, the probe-set with the lowest deviation (standard error of
mean) across the AR and STA samples was used for the analyses.
In cases where different probe-sets for AR and STA revealed lower
deviation, both probe-sets were used. In addition we evaluated if
there were any specific transcriptional changes in biopsies that
were C4d+ AR (n= 3) versus C4d2 AR (n= 10).
Drug discovery targeting IL17 pathway and IL17+ T-
helper cells genes. Affymetrix unique probe-IDs for selected
IL17 pathway and Th17 gene-set genes were uploaded into
MetaCoreTM, an interactive platform of biologically relevant data
to integrate rejection specific genes with annotated functional data
of gene-protein, protein-protein, and protein-compound interac-
tions, together with compound and drug content, and gene disease
relationships (MetaCoreTM; GeneGo, Thomson Reuters, St.
Joseph, MI). The Drug Lookup feature in MetaCoreTM correlated
input genes with deposited data from therapeutic, non-therapeutic,
and secondary drug interactions that had an underlying data entry
in PubMed. Resulting compounds were then filtered for direct
inhibition of target genes, number of genes targeted and their FDA
status. In addition, the underlying PubMed entry was carefully
checked.
QPCR data analysis. Relative gene expression in in-vitro
and in-vivo experiments was assessed by the delta delta Ct method
and fold changes were calculated to either a human or a mouse
universal RNA (Stratagene). Significance was calculated in Excel
(Microsoft Office 2007, Microsoft Inc. USA) and GraphPad Prism
5.04 (GraphPad Software Inc., La Jolla, CA) using a 2-sided
Student T-test and a p-value of 0.05 as threshold for significance.
Results
Discovery of Acute Rejection Specific Redundant IL17
Pathway Enrichment in Human Kidney Transplant
Biopsies Across Independent Patient-Sets
Significance Analysis of Microarray Data (SAM) based two-class
and quantitative Gene Set Analysis (GSA) [25,29] across 3307
curated biologically relevant gene-sets and across 66 whole
genome microarrays identified significantly increasing enrichment
of IL17 pathway genes and genes which had shown significant 2-
fold upregulation (p-value ,0.05) in T-cells experimentally
differentiated into Th17 cells and which were summarized in the
‘‘Th17 gene-set’’ in AR based on false discovery rate (FDR) and p-
value (Table 2).
Across 13 AR graded ARIA or higher and 16 STA two-class
GSA revealed enrichment of the Th17 gene-set with an
FDR=0.2, p= 0, as well as of the IL17 pathway gene-set with
FDR=0.3, p= 0.007. Quantitative GSA (qGSA) across D0,
matched STA, and rejection biopsies separated by grade of
rejection into borderline (BL), ARIA and ARIB showed that the
IL17 pathway gene-set additionally was increasingly enriched with
D0,STA,BL,ARIA,ARIB (IL17 pathway gene-set FDR=0.3
p= 0.011) supporting the relevance of the IL17 pathway in AR.
To validate these findings, we investigated an independent
microarray data-set from 21 STA, and 14 rejection renal allograft
biopsy cases which was publicly available in Gene Expression
Omnibus (GEO, GSE9493). Two-class GSA across the STA and
biopsy confirmed AR (n= 10) showed significant enrichment of
both gene-sets IL17-pathway and Th17 sets in these AR (IL17-
pathway, FDR=0.33, p-value = 0.011; Th17 gene-set,
Table 2. GSA identifies increasing enrichment of IL-17 gene-sets in human renal allograft acute rejection across independent
Patient Data-Sets.
Analysis Gene-Sets p-value FDR
Discovery Data-Set (n=66)
AR vs. STA IL17-Pathway 0.007 0.3
Th17 gene set 0 0.2
D0. STA. BL.ARIA. ARIB IL17-Pathway 0.011 0.3076
Verification Data-Set (n =35)
AR vs. STA IL17-Pathway 0.011 0.33
Th17 gene set 0.026 0.39
STA. BL.AR IL17-Pathway 0.008 0.5
There were total 140 gene-sets significantly enriched in AR in both Data-Sets (FDR= 0.5), the IL-17 pathway and Th17 gene-sets are listed above. Other significant gene-
sets that reached the threshold of FDR = 0.5 included gene-sets associated with innate immune cells (Dendritic Cell, Natural Killer Cell, Granulocyte, Monocyte), and
innate immune responses (CTLA4 pathway, Toll-like receptor pathway, NFKB targets, PD1 signaling), with Cytokine Signaling (IL-10, IL-2, IL-5, IL-22BP, IL-12) as well as
with gene-sets related to Th-differentiation and activation (CD40 signaling, Costimulation, Th1/Th2, Th-Differentiation). Th1 (FDR = 0.3, p = 0.007) and IL-12 (FDR= 0.3,
p = 0.011) had higher FDR and p-values compared to the Th17 and IL-17 gene-sets in our data-set and similar values compared to GSE 9493. Other gene-sets were Graft
versus Host Disease, Autoimmune Thyroiditis, and Antigen processing.
doi:10.1371/journal.pone.0056657.t002
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FDR=0.39, p-value = 0.026). Overall, there were 140 gene-sets
common in both data-sets which were significantly enriched in AR
(FDR=0.5). As the publicly downloaded data-set also included 4
cases among their 14 rejection cases that were defined as
borderline acute rejection, we added a quantitative GSA analysis
which revealed that the IL17 pathway was significantly enriched
following STA,BL,AR (FDR=0.5, p-value 0.008). Due to the
small numbers of BL cases in comparison to the numbers of STA
and AR cases in this data-set, these analyses might be skewed.
Additional QGSA across 10 gene-sets representing the tran-
scriptome of innate and adaptive immune cells (Monocytes,
Natural Killer Cells, Dendritic Cells, Th1-cells, Th2-cells, Th17-
cells, T-regulatory cells, gamma delta T-cells) in response to
experimental activation, and T-cell differentiation (Th-Differenti-
ation, Anergy/Regulation) identified enrichment of the IL17+ T-
helper cell gene-set (Th17, 157 unique genes) [30] in increasing
AR (FDR 0.1, p = 0.047; Table 2). The Th17 gene-set response
was more redundant in the AR biopsies than the Th1 gene-set
response [31] (FDR=0.1, p= 0.05). Genes regulated in the IL17
pathway and the Th17 gene-sets allowed for almost complete
separation of rejecting renal allograft biopsies from non-rejecting
biopsies by hierarchical clustering (Euclidean Distance and Cosine
Dissimilarity) (Figure 2A, 2B). A total of 8 genes (Il-17 pathway,
n = 1; Th17 gene-set, n = 8) were significantly different expressed
between C4d+ AR vs. C4d– AR cases (Student T-test, p,0.05).
Interleukin 8 was common in both gene-sets and showed
significant different expression between C4d+ and C4d– AR cases.
Unsupervised Principal Component Analysis (PCA) for IL17
pathway and Th17 gene-set genes explained 45.1% and 44.7%
respectively of the differences between AR and STA in the first of
three principal components (Figure 2C, 2D). PCA did not
segregate the C4d+ AR from C4d– AR.
Identification of Drugs for Repositioning for IL17 Pathway
Directed Inhibition of AR
AR specific IL17 pathway and IL17+ T-helper cell genes were
interrogated against the MetaCoreTM (GeneGo, St. Joseph, MI)
Compound Database evaluating the interaction of rejection
specific genes against data of 7200 different therapeutic and
non-therapeutic compounds in the drug lookup interface. The
resulting 297 therapeutic and non-therapeutic compounds iden-
tified to interact with one or more of the input genes from the IL17
and IL17+ T-helper cell gene sets were filtered for direct inhibition
and targeting at least 5 genes in the rejection input data-set,
including IL17. Fenofibrate, an FDA approved small molecule
drug for the treatment of hypertriglyceridemia and hypercholes-
terolemia, was inferred to directly inhibit IL17A the major IL17
pathway cytokine and was also suggested to act via the
Th1response directly inhibiting expression of IFN-c the major
Th1 inducing cytokine [10]. In addition to Fenofibrate, our
approach also identified three corticosteroids (Prednisolone,
Budesonid and Flunisolide). Steroids are currently used as
standard immunosuppression and are the mainstay treatment for
an AR episode. This result provided confidence for the validity of
our approach. However, the steroids were not predicted to directly
act via IL17A. As Fenofibrate was hypothesized to directly act on
IL17A as well as on the Th1 cytokine IFN-c, was an FDA
approved small molecule drug with known human safety and side-
effect profiles and established drug delivery and administration
frequency, and with known pleiotropic anti-inflammatory effects
[11], Fenofibrate was selected as drug candidate for AR
repositioning. The subsequent in vitro and in vivo experiments
in our study support likely efficacy for AR in human renal
transplant rejection.
Attenuation of IL17 and IFN-c Gene Expression by
Fenofibrate in CD3/CD28 Stimulated Human PBMC
Anti-CD3/CD28 stimulation of human PBMC from indepen-
dent healthy volunteers upregulated expression of IL17 and IFN-c
in all five individual PBMC; the average fold change for IL17 was
12.15 (p= 0.01), of IFN-c 96.58 (p,0.0001) compared to non-
stimulated PBMC (n=5). Fenofibrate treatment of stimulated
PBMC significantly reversed the upregulation in all cases but one
with respect to IL17 and in all cases with respect to IFN- c: the
average fold change for down regulation was 1.38 and 2.17 for
IL17 (p= 0.02) and IFN-c (p = 0.001) respectively (Figure 3).
Shown are relative fold changes (RQ) in gene expression levels
normalized to 18S and universal RNA for non-stimulated (NS),
stimulated (S) and stimulated and Fenofibrate treated (S+FF)
PBMC.
Experimental in-vivo Evaluation of Fenofibrate for
Efficacy in AR and Characterization of its Immune
Regulatory Effects
Prolonged graft survival in a rodent heart transplant
model of AR by Fenofibrate treatment. A 30-day graft
survival study in BL6/C57 mice heterotropically transplanted with
an allogenic FVB donor heart resulted in significantly prolonged
survival of total allo-mismatch donor hearts transplanted into
Fenofibrate-treated (100 mg/kg/d) recipients (median survival: 25
days; n = 6) compared to non-treated recipients (NT, median
survival: 9.5 days; n = 6) (Wilcoxon log-rank test, p = 0.0007)
(Figure 4) and led to allograft beating beyond day 30 (study end-
point) in two animals. Mice tolerated the Fenofibrate dose well; no
change in total body weight during the treatment was observed.
Allografts in the NT control group were rejected within an average
of 12 days after transplantation. Comparison to standard
immunosuppression (Cyclosporine, Cys, 20 mg/kg/d i.p.) re-
vealed equivalent efficacy of Fenofibrate for extending graft
survival (median survival Cys 30 days) (Figure 4).
Significantly improved graft function with
Fenofibrate. Seven days daily treatment with Fenofibrate-
using the same acute rejection model used for graft survival,
resulted in significantly higher average BS’ (mean BS= 3.5)
compared to NT (mean BS= 2, p,0.001) (Figure 5A). The
chosen dosage of 100 mg/kg/d Fenofibrate was well tolerated by
the mice as there was no change in body weight, liver function and
serum Creatinine (Materials and Methods S1).
Reduction in cellular infiltrates and myocyte damage
with Fenofibrate. Graft tissue from POD7 was assessed by
a single blinded pathologist by microscopic evaluation of H&E
staining applying ISHLT criteria [32,33]. Grafts from Fenofibrate
treated animals revealed decreased cellular infiltrates either uni- or
multifocal but never diffuse, and with- or without myocyte damage
compared to grafts from untreated animals which always showed
diffuse multifocal cellular infiltrates and were always associated
with myocyte damage (Figure 5B).
Significantly reduced numbers of graft infiltrating innate
and adaptive immune cells with Fenofibrate. FACS analysis
of graft infiltrating cells not only confirmed histological evaluation
but further quantified the anti-inflammatory effect of Fenofibrate.
Assessed were total numbers of graft infiltrating total leukocytes
(CD45+), and of differential innate Dendritic- (DC,CD11c),
Natural Killer (ND, NK1.1), Macrophages (F4/80), Neutrophils
(Gr1+)) and adaptive immune Cytotoxic-(CD8), Helper T-(CD4),
and B-(CD220)) cells in Fenofibrate and no-treated grafts at POD7
(Figure 5C). Numbers of cells were corrected for total graft weight.
Fenofibrate significantly decreased the number of CD45+ graft
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infiltrating total leukocytes (p,0.001); more specifically, there was
a significant reduction in antigen presenting DC (p,0.01), in
CD4+ T-helper and CD8+ cytotoxic T-cells, as well as in
infiltrating neutrophils (p,0.01) and NK cells. As IL17 is known
to promote neutrophil infiltration, the observed reduction of
neutrophils in the graft of Fenofibrate treated mice potentially
reflects the IL17 pathway inhibition by Fenofibrate. Infiltrating
macrophages and B-cells were also reduced but numbers did not
reach significance.
Significant inhibition of graft and spleen IL17and Th1
genes in vivo with Fenofibrate. Corroborating the findings of
Fenofibrate on anti-CD3/CD28 stimulated human PBMCs,
Fenofibrate treatment in vivo in cardiac transplanted mice
resulted in reduced gene expression levels of IFN- c and IL17A
(Figure 6A, 6B). IL17A expression in the Fenofibrate treated mice
was only detectable in the transplanted hearts and did not reach
the threshold of detection by QPCR in the recipients’ spleens at
POD7. In grafts IL17 was significantly lower compared to no
treatment (6a, p = 0.0462). In spleens, Fenofibrate significantly
reduced IFN-c expression (6b, p = 0.0094) whereas reduction of
graft IFN-y expression did not quite reach the significance
threshold of p= 0.05 when compared to no-treatment by two
sided Student T-test (6a). Next, we further elucidated the efficacy
of Fenofibrate and expanded graft (Figure 6A) and spleen
(Figure 6B) gene expression analyses to genes up- and downstream
of the Th1 response and IL17 pathway: Fenofibrate reduced the
IL17 stimulating cytokines IL-1b, and TGF-b, as well as of IL-17
downstream TNF in both mice allografts and spleens. IL-6 which
also is upstream of IL17 and together with IL1-b and TGF-
b important for activating the IL17 response was significantly
Figure 2. IL17 pathway- and IL17+ Th- gene sets in human AR: Segregation of AR and STA. Genes from the IL17 pathway gene-set (2a)
and from the Th17 gene-set (2b) were used for hierarchical clustering of post-transplant biopsies and resulted in clear separation of AR and STA after
mean centering arrays and genes (Euclidean Distance, Cosine Dissimilarity). Unsupervised principal component analysis (PCA) of the same samples
using the same genes confirmed the separation of AR and STA (2c, d). A separation of the AR group into C4d+ and C4d- cases was not seen.
doi:10.1371/journal.pone.0056657.g002
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reduced by Fenofibrate in mice allografts only. The Th1 response
was further investigated quantifying the stimulating IL-12 cytokine
expression as well as the Th1 transcription factor STAT4.
Fenofibrate significantly decreased expression of both genes in
mouse spleens, STAT4 was additionally significantly decreased in
the in the graft as compared to mice that were not-treated with
Fenofibrate for AR. QPCR in grafts and spleens from Cys treated
mice at POD7 validated the preferential inhibition of Th1
responses by Cys seen in reduced graft IFN-y (p= 0.0101) and
STAT4 (p= 0.0091) expression, whereas IL17A was not affected
by Cys (p = 0.2180) but even showed a trend towards higher
expression. To address the question, whether the effect of
Fenofibrate to inhibit the IL17 pathway is more dependent on
the related orphan receptors RORc/RORa or on STAT3 (which
induce Th17 cell differentiation), we performed additional QPCR
for RORc, RORa and STAT3 expression in grafts and spleens
from untreated and Fenofibrate treated mice at POD7. There was
no significant difference with treatment in expression of either
RORc (p = 0.26 in the graft; p = 0.59 in the spleen) or RORa
(p = 0.96 in the graft; p = 0.076 in the spleen), but there was
a significant reduction for STAT3 expression in the spleen of
Fenofibrate treated mice at POD7 (p = 0.026), but not in the graft
(p = 0.72). Our results indicate that there is bias towards STAT3
targeted IL17 pathway inhibition by Fenofibrate. Additionally,
there may be differential immune responses in spleen and graft.
Single network formation of rejection specific Fenofibrate
regulated genes. Rejection specific genes which were upregu-
lated in AR and down regulated again by Fenofibrate could be
assembled into a single-network of direct interactions in MetaCor-
eTM network analyses. In this analysis, c-Jun and downstream of c-
Jun, IL-7 receptor (IL7R) were detected as additional genes
interacting with the genes that were regulated by Fenofibrate
(Figure 6C). Our subsequent analyses of c-Jun and IL7R by
QPCR of mice graft and spleen RNA showed that both genes
were upregulated in mice which did not receive Fenofibrate and
that both were down regulated again in mice treated with
Fenofibrate. Specifically, Fenofibrate significantly regulated c-Jun
(p = 0.0293) in mice spleens, and IL7R (p= 0.0162) in mice
allografts. Interestingly, Fenofibrate did not show efficacy on
ROR-a, a transcription factor relevant for IL17 expression in
IL17+ T-helper cells (Figure 6C).
Discussion
The present study elucidates a process of microarray-based and
bioinformatics-driven discovery of transplant rejection specific
functional gene-sets and pathways that are highly relevant to
redundant acute renal allograft rejection, in combination with
a process by which FDA approved drugs can be tested for
repositioning for immunomodulation in human organ trans-
plantation. While most microarray data analysis methods focus
on the identification of individual differentially expressed genes in
two or more conditions, we focused here on sets of biologically
relevant genes in our initial discovery applying gene set analysis
(GSA) as a more robust method with reduced false positive results
and more likely to reveal redundant biologically relevant pathways
Figure 3. Fenofibrate gene expression in human PBMC: Fenofibrate regulates IL17 and IFN-c gene expression in CD3/CD28
stimulated human PBMC. PBMC from healthy individuals (n = 5) were stimulated with CD3/CD28 antibodies (S) leading to significant upregulation
of IL17 and IFN-c which was inhibited by Fenofibrate (S+FF). Values represent mean fold changes versus non-stimulated (NS) cells plus Standard error
of mean calculated using DDCt method and 18S as endogenous control gene; experiments were performed in triplicates. Student T-test for paired
data: * p-value ,0.05. Individual p-values are displayed in Table 3.
doi:10.1371/journal.pone.0056657.g003
Table 3. Effects of Fenofibrate on IFNG and IL17A expression
in human PBMC: Fold changes (Fc) comparing stimulated (S)
to no-stimulated (NS) PBMC (upper part) and comparing
stimulated (S) to stimulated and Fenofibrate treated (S+FF)
PBMC (lower part); direction of the gene expression change
and p-values calculated by two-sided Student T-test.
Fc Direction P-value
S vs. NS IFNG 96.58 Up *** ,0.0001
IL17A 12.15 Up * 0.0142
S vs. S+FF IFNG 2.17 Down ** 0.0014
IL17A 1.38 Down * 0.0224
doi:10.1371/journal.pone.0056657.t003
Drug Repositioning Fenofibrate for Transplantation
PLOS ONE | www.plosone.org 8 February 2013 | Volume 8 | Issue 2 | e56657
underlying graft rejection and describing potential novel drug
targets [26,30,33]. Next, we investigated drugs that already passed
the costly clinical phases of drug development and drug safety in
humans for indications unrelated to organ transplantation, but
could inhibit identified critical gene-sets and pathways in the allo-
immune response. We hypothesized that these target drugs could
be repositioned for suppressing the acute allo-immune response,
providing a more cost effective means of introducing novel drugs
for treatment of acute rejection in organ transplant recipients.
The role of IL17 in innate and adaptive auto- and allo-immune
responses has been investigated by several groups, but is still not
fully understood. Clearly, IL17 was increased in human acute
lung, liver and kidney rejection [4,34,35] and promoted early graft
inflammation [36]. Results in experimental mouse models of
cardiac AR reported that in Th1 transcription factor T-bet
deficient mice, an IL17 response was mounted leading to acute
graft rejection [2,5]. In another study IL17 was also involved in the
acceleration of AR in a T-bet positive background with a full Th1
response [8]. The role of T-bet for IL17 mediated acute rejection
remains controversial, yet most recent evidence suggests, that IL17
plays an accelerated role in a Th1 response suppressed environ-
ment [2]. Our results for IL17 expression in grafts from
transplanted mice treated with Cys which majorly affects the
Th1 response showed higher IL17 expression compared to not-
treatment, whereas IFN-y was significantly lower. As current
immunosuppressive drugs used in transplantation majorly act via
the Th1 response, a potential increased emergence of IL17 in
redundant acute rejection seems to be likely, and our microarray
analyses provides further evidence for the role of IL17 pathway as
an important mechanism of escape in more aggressive acute
allograft rejection in patients on standard immunosuppression
where IL17 appears to drive the intensity of allograft inflamma-
tion. Thus synergistic inhibition of Th1 and IL17 pathways could
be very promising and has been suggested by others [5]. On the
contrary, Huh et al. found that cardiac glycosides inhibited
differentiation of Th17 cells in vitro with high specificity by
binding to the transcription factor RORyt [37]. This did not only
result in a decreased IL17 transcription and production, but the
isolate inhibition of RORyt by cardiac glycosides additionally
resulted in reciprocal increased T-cell IFN-y and FOXP3
expression. The results by Huh et al further support our findings
that a synergistic inhibition of both IFN-y and IL17 pathways as
seen with Fenofibrate may be especially relevant in diseases where
both immune axes play a significant role such as in acute allograft
rejection.
Despite this evidence, IL17 inhibitors are not currently used in
transplantation and in the absence of any available synthetic IL17
inhibitors, we thus pursued the approach of drug repositioning
Fenofibrate, a commercially available FDA approved drug, used
for treatment of hyperlipidemia, and inferred from our study, to
simultaneously inhibit the IL17 pathway and the Th1 mediated
IFN-c pathway in acute graft rejection. Although Fenofibrate has
never been used in transplantation, several studies including the
FIELD study [11], indicated general anti-inflammatory pleiotropic
effects in patients who were treated with Fenofibrate. In addition
to Fenofibrate, steroids currently used in the post-transplant
management of AR, were noted to also regulate many of the input
AR genes in our dataset, supporting the reliability of our
approach, though it is important to note that steroids did not
regulate IL17. As Fenofibrate had been shown to inhibit
expression of both the IL17 and the Th1 response gene IFN-c
[10], Fenofibrate represented a very promising candidate for
repositioning in transplantation. Thus, we characterized the anti-
inflammatory effects of Fenofibrate in organ transplant rejection
related to the inhibition of the IL17 and IFN-c/Th1 responses,
both locally in the allograft and systemically in the spleen of
Figure 4. Graft Survival with Fenofibrate: Fenofibrate treatment alone prolonged cardiac graft survival in transplanted mice. Kaplan
Meyer curve for graft survival data after total allo-mismatch murine heart transplantation was assessed by determining the number of post
operational days (POD) on which transplanted mice showed a palpatable graft beating score (BS). The median number of days grafts of Fenofibrate
treated animals (FF, n = 6) showed beating was 25 compared to 9.5 days in non-treated animals (NT, n = 6). Significance of graft survival was assessed
by Wilcoxon log-rank test (p = 0.0007).
doi:10.1371/journal.pone.0056657.g004
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rejecting animals. We could show profound attenuation of graft
rejection and most importantly Fenofibrate extended graft survival
by 11 days over no-treatment and was almost as efficient as
standard immunosuppression.
The exact mechanism by which Fenofibrate inhibited the IL17
and the Th1 response in our model is not clear, but our gene
expression analyses both in PBMC and in mouse grafts and
spleens suggested an effect upstream of IL17, as the IL17 pathway
activating genes IL1-b, TGF-b and IL6 were significantly
decreased by Fenofibrate. IL6 is known to induce the IL17
pathway promoting the differentiation of IL17 producing T-cells
[38], and was also increased in human AR [35,39]. Importantly
inhibition of the Th1 response in IL-6 deficient mice had
a synergistic effect on attenuating AR [39], similarly to inhibition
of IL-6 in T-bet deficient mice [2], both also leading to decreased
IL17. Here, we showed that Fenofibrate treatment of experimental
AR resulted in simultaneous inhibition of Th1 response genes and
of IL6. Our results further suggest that Fenofibrate also regulates
the IL17 pathway independent from the IL17+ T-helper cell
specific transcription factors ROR-a and –c, as these were not
significantly reduced in mice treated with Fenofibrate. On the
other hand, there was significant down regulation of STAT3 in
spleens from mice treated with Fenofibrate. Only very recently, an
experimental study of murine in-vitro Th-cell differentiation
showed that Fenofibrate inhibited a differentiation of IL17
producing CD4+ T-cells, providing another line of evidence for
Fenofibrate on the IL17-pathway [40]. In this study, the authors
were able to show a dose response curve on IL17 producing T-
Figure 5. Significant improvement of graft function, graft histology and significant reduction in graft cell infiltration with
Fenofibrate treatment. Palpated graft beating in transplanted mice was assessed daily and assigned a beating score (BS). Transplanted mice BS
were significantly improved when treated with Fenofibrate (FF) compared to non- treated ones (NT) (n = 6, p,0.001; shown are mean BS plus SEM),
(a). H&E stainings of mice grafts at POD7 revealed decreased cellular infiltrates and histological damage upon Fenofibrate treatment (b). FACS of
infiltrating cells from the same grafts showed significantly reduced numbers of infiltrating innate and adaptive immune cells in the Fenofibrate
treated mice (*p,0.05, **p,0.01, 2-sided Student T-test, n = 6). Box Plots show median and first and third quartiles of infiltrating cells corrected for
total number of infiltrating cells and total graft weight.
doi:10.1371/journal.pone.0056657.g005
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cells with Fenofibrate [40]. They used TGF-b, IL6, IL4 and IFN-c
to induce the IL17 producing CD4+ T-cells, all of which were
upregulated in our study of experimental AR, and again down
regulated with Fenofibrate.
We also provided additional data on the mechanism of
Fenofibrate by our network analyses, where c-Jun was found to
actually act on all genes regulated by Fenofibrate, either directly or
indirectly. The protein c-Jun in combination with c-Fos forms the
activator protein 1 (AP-1) early response transcription factor.
Inhibition of AP-1 using decoy oligonucleotides at day of
transplantation was efficient in attenuating cardiac vasculopathy
in rats [41]. Here, c-jun was significantly upregulated in mice
allografts with AR, and Fenofibrate treatment led to significant
down regulation of c-Jun in cardiac grafts compared to no
treatment, suggesting a potential central anti-inflammatory mech-
anism of Fenofibrate on T-cells.
A retrospective analysis of human transplant recipients receiving
Fenofibrate is currently under way to evaluate any synergistic
protective role of Fenofibrate on acute and chronic graft rejection
(Roedder et al, manuscript under preparation). Additional analysis
of the genome wide association study of inflammatory biomarker
changes in response to Fenofibrate treatment [42] can shed
additional light on selecting patients prior to transplantation that
can benefit from a combination of Fenofibrate treatment with
standard immunosuppression. This data supports that, in addition
to standard immunosuppression, the inhibition of the IL17
pathway, may be effective in reducing the incidence and severity
of acute rejection and thus positively impact on long term
outcomes after organ transplantation and can potentially be
achieved using Fenofibrate.
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